Keyphrases
Non-small Cell Lung Cancer (NSCLC)
100%
Ongoing Clinical Trials
100%
Status Report
100%
Progression-free Survival
33%
Patient Selection
33%
United States
16%
Clinical Trials
16%
Overall Survival
16%
Phase III Clinical Trial
16%
Phase II Trial
16%
Tumor Response Rate
16%
Pharmaceutical Industry
16%
New Agents
16%
Open Study
16%
Phase II Clinical Trial
16%
Advanced Stage Disease
16%
Biomarker Analysis
16%
Search Options
16%
Advanced Search
16%
Primary Sponsors
16%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Non Small Cell Lung Cancer
100%
Biological Marker
50%
Progression Free Survival
33%
Disease
16%
Neoplasm
16%
Overall Survival
16%
Phase II Trials
16%
Nursing and Health Professions
Non Small Cell Lung Cancer
100%
Biological Marker
50%
Progression Free Survival
33%
Patient Selection
33%
Neoplasm
16%
Overall Survival
16%
Disease
16%
Biochemistry, Genetics and Molecular Biology
Clinical Trial
100%
Progression Free Survival
33%
Overall Survival
16%
Phase II Trials
16%